Charles River Laboratories International Inc. (CRL)

135.20
0.92 0.68
NYSE : Commercial Services
Prev Close 136.12
Open 136.07
Day Low/High 134.88 / 136.49
52 Wk Low/High 103.00 / 149.06
Volume 174.36K
Avg Volume 366.70K
Exchange NYSE
Shares Outstanding 48.75M
Market Cap 6.64B
EPS 4.70
P/E Ratio 29.46
Div & Yield N.A. (N.A)

Latest News

Don't Jump Into Charles River Labs Just Yet

Don't Jump Into Charles River Labs Just Yet

CRL could weaken further in upcoming weeks for a better buying opportunity.

The Barbell Economy: Cramer's 'Mad Money' Recap (Thursday 6/13/19)

The Barbell Economy: Cramer's 'Mad Money' Recap (Thursday 6/13/19)

Jim Cramer looks at retail, specifically the companies that are doing well for working-class Americans, and those that cater to high-end customers -- a 'barbell economy,' he says.

Home Depot, Neogenomics, Ball Corp.: 'Mad Money' Lightning Round

Home Depot, Neogenomics, Ball Corp.: 'Mad Money' Lightning Round

Jim Cramer is taking a closer look at Home Depot, Neogenomics, Ball Corp., Mercer International, Lumentum Holdings, Synopsys, Olin, and CommScope.

Charles River Laboratories To Present At Jefferies And Goldman Sachs Investor Conferences

Charles River Laboratories To Present At Jefferies And Goldman Sachs Investor Conferences

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including: Jefferies 2019 Global Healthcare Conference in New York on Wednesday, June 5 th, at 8:30 a.

Charles River Laboratories Invests In Resero Analytics™

Charles River Laboratories Invests In Resero Analytics™

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has invested in Resero Analytics™, a software company focused on providing solutions to the biopharmaceutical industry to harness its data.

Charles River Laboratories Announces First-Quarter 2019 Results

Charles River Laboratories Announces First-Quarter 2019 Results

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2019.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Charles River Laboratories International, Inc. - CRL

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Charles River Laboratories International, Inc. - CRL

NEW YORK, May 1, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Charles River Laboratories International, Inc.

Charles River Laboratories Completes The Acquisition Of Citoxlab

Charles River Laboratories Completes The Acquisition Of Citoxlab

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Citoxlab for €448 million in cash (or approximately $500 million based on current exchange rates), subject to...

Charles River Laboratories Schedules First-Quarter 2019 Earnings Release And Conference Call

Charles River Laboratories Schedules First-Quarter 2019 Earnings Release And Conference Call

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2019 financial results on Tuesday, May 7 th, before the market opens.

Behind Every Patient Stands Thousands Of Scientists And Researchers Collaborating To Develop Life-saving Drugs. Jenne's Story Highlights The Importance Of That Work.

Behind Every Patient Stands Thousands Of Scientists And Researchers Collaborating To Develop Life-saving Drugs. Jenne's Story Highlights The Importance Of That Work.

Charles River Laboratories International, Inc. (NYSE: CRL) and CHDI Foundation today announced a five-year extension of their ongoing collaboration.

Charles River Laboratories Highlights Commitment To Oncology Research At 2019 AACR Annual Meeting

Charles River Laboratories Highlights Commitment To Oncology Research At 2019 AACR Annual Meeting

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting, with 19 scientific posters and two oral presentations to highlight...

Do Your Homework: Cramer's 'Mad Money' Recap (Tuesday 3/12/19)

Do Your Homework: Cramer's 'Mad Money' Recap (Tuesday 3/12/19)

Jim Cramer looks at Boeing, Dick's Sporting Goods and more -- and shows investors how to really understand the markets and stock-picking.

Charles Schwab, Invitae, Weibo: 'Mad Money' Lightning Round

Charles Schwab, Invitae, Weibo: 'Mad Money' Lightning Round

Jim Cramer weighs in on Charles Schwab, Invitae, Weibo, Alibaba, Charles River Labs, AeroVironment, Ormat Technologies.

Why Charles River Labs Is the Biotech Stock to Buy: Jim Cramer

Why Charles River Labs Is the Biotech Stock to Buy: Jim Cramer

Ready to diversify your portfolio but unfamiliar with the biotech space? Here's a stock pick from Jim Cramer.

Charles River Laboratories To Present At Raymond James And Barclays Investor Conferences

Charles River Laboratories To Present At Raymond James And Barclays Investor Conferences

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including: Raymond James 40 th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 5 th, at...

Charles River Laboratories Could Suffer a Pullback Before Moving Still Higher

Charles River Laboratories Could Suffer a Pullback Before Moving Still Higher

CRL looks strong and probably capable of further gains but in the short-run we could see a pullback.

Fed Is the Bulls' Friend: Cramer's 'Mad Money' Recap (Tuesday 2/26/19)

Fed Is the Bulls' Friend: Cramer's 'Mad Money' Recap (Tuesday 2/26/19)

Jim Cramer says the fact that Fed Chair Jay Powell knows that things are slowing down may be the best thing this market has going for it.

Charles River Laboratories Announces Fourth-Quarter And Full-Year 2018 Results And Provides 2019 Guidance

Charles River Laboratories Announces Fourth-Quarter And Full-Year 2018 Results And Provides 2019 Guidance

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2018 and provided guidance for 2019.

Charles River Laboratories Signs Binding Offer To Acquire Citoxlab

Charles River Laboratories Signs Binding Offer To Acquire Citoxlab

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a binding offer to acquire Citoxlab for €448 million in cash (or approximately $510 million based on current exchange rates), subject to customary closing...

Charles River Laboratories And Toxys Enter Agreement To Offer ToxTracker® In North America

Charles River Laboratories And Toxys Enter Agreement To Offer ToxTracker® In North America

Charles River Laboratories International, Inc (NYSE: CRL) and Toxys have entered into an agreement to offer access to ToxTracker® in North America.

Charles River Laboratories Schedules Fourth-Quarter 2018 Earnings And 2019 Guidance Release And Conference Call

Charles River Laboratories Schedules Fourth-Quarter 2018 Earnings And 2019 Guidance Release And Conference Call

Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2018 financial results and provide 2019 guidance on Wednesday, February 13 th, before the market opens.

Charles River Laboratories Selected For 2019 Bloomberg Gender-Equality Index

Charles River Laboratories Selected For 2019 Bloomberg Gender-Equality Index

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it is pleased to have been selected as one of 230 companies for the 2019 Bloomberg Gender-Equality Index (GEI), which distinguishes companies committed to transparency in...

Charles River Laboratories And Atomwise Form A Strategic Alliance To Provide Integrated, Artificial Intelligence-Driven Drug Discovery

Charles River Laboratories And Atomwise Form A Strategic Alliance To Provide Integrated, Artificial Intelligence-Driven Drug Discovery

Charles River Laboratories International, Inc. (NYSE: CRL) and Atomwise, Inc.

Charles River Laboratories To Present At J.P. Morgan Healthcare Conference

Charles River Laboratories To Present At J.P. Morgan Healthcare Conference

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 37 th Annual J.

Keep Your Head Up: Cramer's 'Mad Money' Recap (Thursday 12/6/18)

Keep Your Head Up: Cramer's 'Mad Money' Recap (Thursday 12/6/18)

Jim Cramer offers his views on how to hang on in scary markets.

Charles River Laboratories To Present At Evercore ISI Investor Conference

Charles River Laboratories To Present At Evercore ISI Investor Conference

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Evercore ISI HealthConX Conference in Boston on Thursday, November 29 th, at 11:00 a.

Charles River Laboratories Continues Commitment To Oncology Drug Discovery

Charles River Laboratories Continues Commitment To Oncology Drug Discovery

Charles River Laboratories International, Inc. (NYSE: CRL) today announced new additions to the Tumor Model Compendium.

Charles River Laboratories Announces Third-Quarter 2018 Results

Charles River Laboratories Announces Third-Quarter 2018 Results

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2018.

TheStreet Quant Rating: B (Buy)